热门资讯> 正文
Valneva And Pfizer Announced Further Immunogenicity And Safety Data From VLA15-221 Phase 2 Study Following A Second Booster Vaccination Of Their Lyme Disease Vaccine Candidate, VLA15, Given One Year After Receiving The First Booster Dose
2024-09-03 17:39
The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
